Yonsei University

UNC researchers, Bryan Roth and Grégory Scherrer, developed a gene therapy using chemogenetics to reduce pain in mouse models. The system, mHCAD, targets peripheral nervous system neurons, reducing pain perception. Delivery via adeno-associated virus could make this therapy a future treatment for chronic pain.

Handok Pharmaceutical, under Chairman Kim Young-jin, has led open innovation since 2007, partnering with companies like Genexine and ABL Bio for new drug development. HDB001A, a next-gen anticancer drug, is a key product of this strategy, with phase 2/3 trials approved by the FDA. Handok aims to enhance productivity through digital and AI, launching new products like MPAVELI to offset sales from expiring contracts. The long-term goal is to become a 'best partner' in the Korean market and expand to Southeast Asia.

Alteogen CEO Park Soon-jae's success is attributed to his focus on core business and timely adaptation to global trends, transforming the company from a small lab to a leading bio firm. His strategy of short-term biosimilar exports and long-term 'bio-better' development has led to significant growth, supported by key investors.

201 medical students dropped out in 2023, up 12.3% from 2022. Seoul and Jeolla regions had the highest dropouts. Chungnam National University had the most, with 16. Jongro Academy predicts more dropouts this year due to students on leave.